alerting health professionals that methylphenidate (Ritalin, etc) might be carcinogenic
February 1996
The FDA is alerting health professionals that methylphenidate (Ritalin, etc) might be carcinogenic.
They're requiring new info in the package insert...and having manufacturers send out a letter to prescribers.
This concern is based on toxicology studies which show an increased incidence of liver tumors in some mice...but not in rats.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote